Merck's hep C combo hits cure-rate goal in IV drug users; Meda's Elidel could suffer on Valeant pharmacy snafu;

> Merck & Co.'s ($MRK) forthcoming hepatitis C regimen got a boost from new data showing that it delivered a high cure rate in patients who use intravenous drugs, the "hot core" of people with the disease. Report

> Sweden's Meda, whose dermatology drug Elidel is licensed in the U.S. to Valeant Pharmaceuticals ($VRX), could see sales disruptions from its partner's specialty pharmacy woes. Report

> Gilead Sciences ($GILD) won expanded FDA approval for its blockbuster hepatitis C combo pill Harvoni, extending use to new subtypes of hep C and to patients co-infected with HIV. Report

And Finally... Professional cycling's Team Novo Nordisk met with Pope Francis for World Diabetes Day last week. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.